002620.KS
Jeil Pharma Holdings Inc
KSC · Healthcare · Drug Manufacturers - Specialty & Generic · KR
KRW 7,650.00
+1.19%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 622.5B | 657.6B | 779.8B | 804.0B | 793.0B |
| Cost of Revenue | 376.8B | 407.4B | 573.3B | 589.5B | 612.5B |
| Gross Profit | 245.7B | 226.3B | 206.5B | 214.6B | 180.5B |
| Operating Expenses | |||||
| R&D Expense | 58.1B | 43.7B | 37.4B | 46.0B | 41.6B |
| SG&A Expense | 122.6B | 96.0B | 90.0B | 79.2B | 79.4B |
| General & Admin Expense | 35.5B | 46.3B | 45.0B | 42.0B | 43.2B |
| Selling & Marketing Expense | 35.7B | 49.7B | 45.0B | 37.2B | 36.2B |
| Other Expenses | 52.2B | 71.5B | 90.6B | 68.4B | 67.0B |
| Total Operating Expenses | 233.0B | 211.2B | 218.1B | 193.7B | 188.0B |
| Cost and Expenses | 612.4B | 618.0B | 791.4B | 783.2B | 800.5B |
| Operating Income (EBIT) | (4.2B) | 15.1B | (11.6B) | 20.9B | (7.5B) |
| Non-Operating | |||||
| Interest Income | 2.1B | 1.9B | 1.7B | 1.7B | 499.5M |
| Interest Expense | 7.4B | 7.5B | 8.9B | 10.7B | 6.0B |
| Net Interest Income | (5.3B) | (5.6B) | (7.2B) | (8.9B) | (5.5B) |
| Other Non-Op Income/Expense | 28.8B | 24.3B | (50.1B) | (34.9B) | (76.3B) |
| Non-Operating Income (excl Interest) | (9.3B) | — | 41.2B | 24.2B | 70.4B |
| EBT (Pre-Tax Income) | 24.7B | 39.5B | (61.6B) | (14.0B) | (83.9B) |
| Income Tax Expense | (759.6M) | 4.7B | 4.8B | (740.8M) | (715.6M) |
| Bottom Line | |||||
| Net Income | 8.4B | 14.6B | (51.2B) | (16.2B) | (83.1B) |
| Earnings from Cont. Ops | 25.4B | 34.8B | (66.4B) | (13.2B) | (83.1B) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 8.4B | 14.6B | (51.2B) | (16.2B) | (74.6B) |
| Per Share | |||||
| Basic EPS | ₩550 | ₩953 | (₩3,323) | (₩1,059) | (₩5,416) |
| Diluted EPS | ₩550 | ₩953 | (₩3,323) | (₩1,059) | (₩5,416) |
| Revenue Per Share | ₩40,551 | ₩41,170 | ₩50,799 | ₩52,400 | ₩51,655 |
| Shares | |||||
| Basic Shares Outstanding | 15.4M | 16.0M | 15.4M | 15.3M | 15.4M |
| Diluted Shares Outstanding | 15.4M | 16.0M | 15.4M | 15.4M | 15.4M |
| Profitability Metrics | |||||
| EBITDA | (39.7B) | 30.0B | (38.7B) | 9.2B | (67.0B) |
| D&A | 15.3B | 14.9B | 14.1B | 12.6B | 10.9B |
| EBIT | 12.7B | 15.1B | (52.8B) | (3.3B) | (77.9B) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026